KENVUE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.39 USD | -1.29% |
|
-4.72% | -14.58% |
| Jun. 04 | Transcript : Kenvue Inc. Presents at 21st Annual dbAccess Global Consumer Conference 2024, Jun-04-2024 02:45 PM | |
| May. 23 | Some of the biggest splits in Corporate America | RE |
Business Summary
- health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.);
- body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.);
- other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.).
Product marketing is assured through direct sales, distributors and the Internet.
Number of employees: 22,000
Sales per Business
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Self Care
41.8
%
| 6,030 | 40.3 % | 6,451 | 41.8 % | +6.98% |
Essential Health
29.9
%
| 4,570 | 30.6 % | 4,615 | 29.9 % | +0.98% |
Skin Health and Beauty
28.3
%
| 4,350 | 29.1 % | 4,378 | 28.3 % | +0.64% |
Sales per region
| USD in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
43.8
%
| 6,599 | 44.1 % | 6,767 | 43.8 % | +2.55% |
Europe, Middle East, and Africa
21.9
%
| 3,188 | 21.3 % | 3,388 | 21.9 % | +6.27% |
Asia-Pacific
20.1
%
| 3,146 | 21.0 % | 3,107 | 20.1 % | -1.24% |
Latin America
8.7
%
| 1,198 | 8.0 % | 1,339 | 8.7 % | +11.77% |
North America
5.5
%
| 819 | 5.5 % | 843 | 5.5 % | +2.93% |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,919,764,663 | 1,914,390,764 ( 99.72 %) | 4,950,000 ( 0.2578 %) | 99.72 % |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
McNeil AB
 McNeil AB Pharmaceuticals: MajorHealth Technology McNeil AB operates within the consumer health care division that develops and manufactures medicines. It specializes in the manufacture of self-care medicines. The firm offers NICORETTE products for the global market. The company was founded in December 2006 and is headquartered in Helsinborg, Sweden. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
18.39
USD
Average target price
22.54
USD
Spread / Average Target
+22.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.58% | 35.21B | |
| +14.00% | 394B | |
| +15.68% | 140B | |
| +17.79% | 77.03B | |
| -17.63% | 43.2B | |
| +6.89% | 35.09B | |
| +13.44% | 18.89B | |
| +26.23% | 17.49B | |
| +10.03% | 13.01B | |
| +17.19% | 9.65B |
- Stock Market
- Equities
- KVUE Stock
- Company Kenvue Inc.
